Axsome Therapeutics Q4 EPS $(2.08) Misses $(1.15) Estimate, Sales $71.53M Beat $67.69M Estimate
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics (NASDAQ:AXSM) reported Q4 earnings with a loss of $(2.08) per share, missing the $(1.15) estimate by 80.87%, and a 47.52% decrease from last year. However, their sales of $71.53M exceeded estimates by 5.67%, marking a 193.50% increase from the previous year.

February 20, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Axsome Therapeutics reported a larger than expected quarterly loss but exceeded sales estimates, indicating mixed financial health.
The larger than expected loss per share could negatively impact investor sentiment and stock price in the short term. However, the significant beat on sales estimates and the impressive year-over-year sales growth could offset some of the negative impact, suggesting a neutral short-term price direction.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100